Major therapeutic advances and new perspectives in onco-hematology

被引：7

作者：

Bay, Jacques-Olivier ^{[1
,2
]}

Guieze, Romain ^{[1
,2
]}

Ravinet, Aurelie ^{[1
]}

Lemal, Richard ^{[1
]}

Xhaard, Alienor ^{[3
]}

Bailly, Sebastien ^{[1
]}

Molucon-Chabrot, Cecile ^{[1
]}

Hermet, Eric ^{[1
]}

Biau, Julian ^{[4
]}

Verrelle, Pierre ^{[4
]}

de latour, Regis Peffault ^{[3
]}

Tournilhac, Olivier ^{[1
,2
]}

机构：

[1] CHU Clermont Ferrand, Serv Hematol Clin Adulte & Therapie Cellulaire, F-63003 Clermont Ferrand 01, France

[2] Univ Auvergne, EA7283, CIC501, F-63000 Clermont Ferrand, France

[3] Hop St Louis, Serv Hematol Greffe, F-75010 Paris, France

[4] Ctr Jean Perrin, Serv Radiotherapie, F-63000 Clermont Ferrand, France

来源：

BULLETIN DU CANCER | 2013年 / 100卷 / 06期

关键词：

cancer; chemotherapy; targeted therapies; allo-graft; perspective; retrospective; CHRONIC LYMPHOCYTIC-LEUKEMIA; EXTENDED-FIELD RADIOTHERAPY; BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; ABL TYROSINE KINASE; HODGKINS-LYMPHOMA; COMBINATION CHEMOTHERAPY; RADIATION-THERAPY; BODY IRRADIATION;

D O I：

10.1684/bdc.2013.1751

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hematology Oncology has a rich history including few crucial therapeutic innovations. These were possible because of the evolution of the cell and molecular biology allowing a better understanding of basic mechanisms of cancerogenesis. We propose here to summarize the most important therapeutic innovations since the beginning of Hematology/Oncology history. We also describe evolution of therapeutic strategies themselves. New insights and therapeutic perspectives for next future are also discussed.

引用

页码：587 / 599

页数：13

共 92 条

[21] Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia
Cornely, Oliver A.
Maertens, Johan
Winston, Drew J.
Perfect, John
Ullmann, Andrew J.
Walsh, Thomas J.
Helfgott, David
Holowiecki, Jerzy
Stockelberg, Dick
Goh, Yeow-Tee
Petrini, Mario
Hardalo, Cathy
Suresh, Ramachandran
Angulo-Gonzalez, David
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (04) : 348 - 359
[22] DAUSSET J., 1958, ACTA HAEMATOL, V20, P156
[23] COMBINATION CHEMOTHERAPY IN TREATMENT OF ADVANCED HODGKINS DISEASE
DEVITA, VT
SERPICK, AA
CARBONE, PP
[J]. ANNALS OF INTERNAL MEDICINE, 1970, 73 (06) : 881 - +
[24] Chlorambucil in indolent chronic lymphocytic leukemia
Dighiero, G
Maloum, K
Desablens, B
Cazin, B
Navarro, M
Leblay, R
Leporrier, M
Jaubert, J
Lepeu, G
Dreyfus, B
Binet, JL
Travade, P
Turpin, FL
Tertian, G
Bichoffe, A
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (21) : 1506 - 1514
[25] Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, Li
Ley, Timothy J.
Larson, David E.
Miller, Christopher A.
Koboldt, Daniel C.
Welch, John S.
Ritchey, Julie K.
Young, Margaret A.
Lamprecht, Tamara
McLellan, Michael D.
McMichael, Joshua F.
Wallis, John W.
Lu, Charles
Shen, Dong
Harris, Christopher C.
Dooling, David J.
Fulton, Robert S.
Fulton, Lucinda L.
Chen, Ken
Schmidt, Heather
Kalicki-Veizer, Joelle
Magrini, Vincent J.
Cook, Lisa
McGrath, Sean D.
Vickery, Tammi L.
Wendl, Michael C.
Heath, Sharon
Watson, Mark A.
Link, Daniel C.
Tomasson, Michael H.
Shannon, William D.
Payton, Jacqueline E.
Kulkarni, Shashikant
Westervelt, Peter
Walter, Matthew J.
Graubert, Timothy A.
Mardis, Elaine R.
Wilson, Richard K.
DiPersio, John F.
[J]. NATURE, 2012, 481 (7382) : 506 - 510
[26] Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Doehner, Hartmut
Estey, Elihu H.
Amadori, Sergio
Appelbaum, Frederick R.
Buechner, Thomas
Burnett, Alan K.
Dombret, Herve
Fenaux, Pierre
Grimwade, David
Larson, Richard A.
Lo-Coco, Francesco
Naoe, Tomoki
Niederwieser, Dietger
Ossenkoppele, Gert J.
Sanz, Miguel A.
Sierra, Jorge
Tallman, Martin S.
Loewenberg, Bob
Bloomfield, Clara D.
[J]. BLOOD, 2010, 115 (03) : 453 - 474
[27] Neurokinin-1 Receptor Antagonists for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review
dos Santos, Lucas Vieira
Souza, Fabiano Hahn
Brunetto, Andre Tesainer
Sasse, Andre Deeke
da Silveira Nogueira Lima, Joao Paulo
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (17): : 1280 - 1292
[28] Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, BJ
Tamura, S
Buchdunger, E
Ohno, S
Segal, GM
Fanning, S
Zimmermann, J
Lydon, NB
[J]. NATURE MEDICINE, 1996, 2 (05) : 561 - 566
[29] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Druker, BJ
Talpaz, M
Resta, DJ
Peng, B
Buchdunger, E
Ford, JM
Lydon, NB
Kantarjian, H
Capdeville, R
Ohno-Jones, S
Sawyers, CL
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) : 1031 - 1037
[30] Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma:: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group
Engert, A
Schiller, P
Josting, A
Herrmann, R
Koch, P
Sieber, M
Boissevain, F
de Wit, M
Mezger, J
Dühmke, E
Willich, N
Müller, RP
Schmidt, BF
Renner, H
Müller-Hermelink, HK
Pfistner, B
Wolf, J
Hasenclever, D
Löffler, M
Diehl, V
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (19) : 3601 - 3608

← 1 2 3 4 5 6 7 8 9 10 →